<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03503630</url>
  </required_header>
  <id_info>
    <org_study_id>BIO-2017-0422</org_study_id>
    <secondary_id>MS100070_0021 ISS</secondary_id>
    <nct_id>NCT03503630</nct_id>
  </id_info>
  <brief_title>Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma</brief_title>
  <official_title>Short-course Radiation Followed by mFOLFOX-6 Plus COMPOUND 2055269 for Locally-advanced Rectal Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ali Shamseddine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Phoenix Clinical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>American University of Beirut Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to show that the addition of COMPOUND 2055269, an&#xD;
      immunotherapeutic drug, to Folfox chemotherapy will improve the pathologic complete response&#xD;
      rate in patients with locally advanced rectal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to show that the addition of COMPOUND 2055269, an&#xD;
      immunotherapeutic drug, to Folfox chemotherapy will improve the pathologic complete response&#xD;
      rate in patients with locally advanced rectal cancer.&#xD;
&#xD;
      COMPOUND 2055269 has demonstrated meaningful clinical activity across various tumor types and&#xD;
      treatment settings. No clinical trial is conducted over COMPOUND 2055269 in locally-advanced&#xD;
      rectal adenocarcinoma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 20, 2018</start_date>
  <completion_date type="Anticipated">June 2, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of the study is to evaluate the pathologic complete response (pCR) rate following short-course radiation then mFOLFOX-6/COMPOUND 2055269</measure>
    <time_frame>After 17 weeks (once surgery is done)</time_frame>
    <description>Will be done via pathologic assessment on the surgical specimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients who remain progression free at 3 years.</measure>
    <time_frame>3 years</time_frame>
    <description>1) Progression free survival is measured by imaging and serial tumor markers during follow up visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PD-L1 expression and T-cell infiltration changes after treatment</measure>
    <time_frame>At day 10 biopsy and after 17 weeks (once surgery is done)</time_frame>
    <description>2) PD-L1 &amp; T cell infiltration is measured by a pathology assessment on day 10 and after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment- related adverse events as assessed by NCI-CTCAE v4.0</measure>
    <time_frame>3 years</time_frame>
    <description>Treatment- related adverse events are assessed by NCI-CTCAE v4.0 in each visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of the patients in a neoadjuvant setting with COMPOUND 2055269 as assessed by FACT-C questionnaire</measure>
    <time_frame>3 years</time_frame>
    <description>Quality of life is measured via FACT-C questionnaire in each visit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Locally Advanced Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Locally advanced rectal cancer patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Week 1: D1-5: radiotherapy 25 Gy in 5 fractions&#xD;
mFOLFOX-6: Oxaliplatin 85 mg/m2 in a 2-hour infusion Leucovorin 400 mg/m² over 2 hours Bolus fluorouracil 400 mg/m² followed by a 48-hour infusion of fluorouracil 2,400 mg/m² + COMPOUND 2055269 10 mg/kg every 2 weeks (first administration at D15, for a total of 6 cycles)&#xD;
Week 16 or 17 (2 to 3 weeks after last cycle of chemotherapy + COMPOUND 2055269): Total Mesorectal Excision</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COMPOUND 2055269</intervention_name>
    <description>COMPOUND 2055269 to be given every 2 weeks with chemotherapy for 6 cycles</description>
    <arm_group_label>Locally advanced rectal cancer patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Radiotherapy 25 Gy to be given on Days 1-5</description>
    <arm_group_label>Locally advanced rectal cancer patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mFOLFOX</intervention_name>
    <description>Given every 2 weeks for 6 cycles</description>
    <arm_group_label>Locally advanced rectal cancer patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Total Mesorectal Excision</intervention_name>
    <description>Surgery to be done 2-3 weeks after last cycle of chemotherapy and COMPOUND 2055269</description>
    <arm_group_label>Locally advanced rectal cancer patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged ≥18 years.&#xD;
&#xD;
          2. Locally-advanced rectal cancer (cT2 N1-3, cT3 N0-3, evidence of extramural vascular or&#xD;
             mesorectal fascia involvement).&#xD;
&#xD;
          3. &lt;12 cm from anal verge.&#xD;
&#xD;
          4. Histologically proven rectal adenocarcinoma.&#xD;
&#xD;
          5. ECOG performance score ≤ 1.&#xD;
&#xD;
          6. Have adequate organ function by meeting the following:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1.5 × 109/L;&#xD;
&#xD;
               -  Platelet count ≥ 100 × 109/L;&#xD;
&#xD;
               -  Hemoglobin ≥ 9 g/dL;&#xD;
&#xD;
               -  Total bilirubin level ≤ 1.5 × the upper limit of normal (ULN) range;&#xD;
&#xD;
               -  AST and ALT levels ≤ 2.5 × ULN or AST and ALT levels ≤ 5 x ULN (for subjects with&#xD;
                  documented metastatic disease to the liver);&#xD;
&#xD;
               -  Estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft- Gault&#xD;
                  formula (or local institutional standard method).&#xD;
&#xD;
          7. Negative serum or urine pregnancy test at screening for women of childbearing&#xD;
             potential.&#xD;
&#xD;
          8. Highly effective contraception for both male and female subjects throughout the study&#xD;
             and for at least 30 days after last COMPOUND 2055269 treatment administration if the&#xD;
             risk of conception exists.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Distant metastasis (M1).&#xD;
&#xD;
          2. Patients with T2 N0 or T4.&#xD;
&#xD;
          3. Recurrent rectal cancer.&#xD;
&#xD;
          4. Symptoms or history of peripheral neuropathy.&#xD;
&#xD;
          5. Prior radiotherapy or chemotherapy.&#xD;
&#xD;
          6. Current use of immunosuppressive medication, except for the following:&#xD;
&#xD;
               -  Intranasal, inhaled, topical steroids, or local steroid injection (e.g.,&#xD;
                  intraarticular injection);&#xD;
&#xD;
               -  Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or&#xD;
                  equivalent;&#xD;
&#xD;
               -  Steroids as premedication for hypersensitivity reactions (e.g., CT scan&#xD;
                  premedication).&#xD;
&#xD;
          7. Active autoimmune disease that might deteriorate when receiving an immunostimulatory&#xD;
             agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid&#xD;
             diseases not requiring immunosuppressive treatment are eligible.&#xD;
&#xD;
          8. Vaccination within 4 weeks of the first dose of COMPOUND 2055269 and while on trials&#xD;
             is prohibited except for administration of inactivated vaccines.&#xD;
&#xD;
          9. Active infection requiring systemic therapy.&#xD;
&#xD;
         10. Known history of testing positive for the human immunodeficiency virus or known&#xD;
             acquired immunodeficiency syndrome.&#xD;
&#xD;
         11. Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening (positive&#xD;
             HBV surface antigen or HCV RNA if anti-HCV antibody screening test positive).&#xD;
&#xD;
         12. Known prior severe hypersensitivity to investigational product or any component in its&#xD;
             formulations, including known severe hypersensitivity reactions to monoclonal&#xD;
             antibodies (NCI CTCAE v4.03 Grade ≥ 3).&#xD;
&#xD;
         13. Clinically significant (i.e., active) cardiovascular disease: cerebral vascular&#xD;
             accident/stroke (&lt; 6 months prior to enrollment), myocardial infarction (&lt; 6 months&#xD;
             prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart&#xD;
             Association Classification Class II), or serious cardiac arrhythmia requiring&#xD;
             medication.&#xD;
&#xD;
         14. Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 Grade &gt; 1); however,&#xD;
             alopecia, sensory neuropathy Grade ≤ 2, or other Grade ≤ 2 not constituting a safety&#xD;
             risk based on investigator's judgment are acceptable.&#xD;
&#xD;
         15. Prior organ transplantation including allogenic stem-cell transplantation.&#xD;
&#xD;
         16. Other severe acute or chronic medical conditions including immune colitis,&#xD;
             inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric&#xD;
             conditions including recent (within the past year) or active suicidal ideation or&#xD;
             behavior; or laboratory abnormalities that may increase the risk associated with study&#xD;
             participation or study treatment administration or may interfere with the&#xD;
             interpretation of study results and, in the judgment of the investigator, would make&#xD;
             the patient inappropriate for entry into this study.&#xD;
&#xD;
         17. Concurrent treatment with a non-permitted drug.&#xD;
&#xD;
         18. Patients suspected by the physician that he/she will not compliant to the protocol&#xD;
             conduct.&#xD;
&#xD;
         19. Pregnant or breastfeeding patients.&#xD;
&#xD;
         20. Patient participating in another clinical trial.&#xD;
&#xD;
         21. Patient who is not willing to sign the consent form.&#xD;
&#xD;
         22. Any psychiatric condition that would prohibit the understanding or rendering of&#xD;
             informed consent.&#xD;
&#xD;
         23. Legal incapacity or limited legal capacity patients receiving other oncology specific&#xD;
             medication not authorized in the protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ali I Shamseddine, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>American University of Beirut Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ali I Shamseddine, M.D.</last_name>
    <phone>00961-1-350000</phone>
    <phone_ext>5390</phone_ext>
    <email>as04@aub.edu.lb</email>
  </overall_contact>
  <location>
    <facility>
      <name>King Hussein Cancer Center</name>
      <address>
        <city>Amman</city>
        <country>Jordan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rim Turfa, M.D.</last_name>
      <phone>+96265300460</phone>
      <phone_ext>1656</phone_ext>
      <email>rturfa@khcc.jo</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>American University of Beirut Medical Center</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali I Shamseddine, M.D.</last_name>
      <phone>00961-1-350000</phone>
      <phone_ext>5390</phone_ext>
      <email>as04@aub.edu.lb</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôtel Dieu de France</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Kattan, M.D.</last_name>
      <phone>+9611615300</phone>
      <phone_ext>8013</phone_ext>
      <email>kattan62@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Jordan</country>
    <country>Lebanon</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>March 29, 2018</study_first_submitted>
  <study_first_submitted_qc>April 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2018</study_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>American University of Beirut Medical Center</investigator_affiliation>
    <investigator_full_name>Ali Shamseddine</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Locally advanced rectal cancer</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Short course radiation</keyword>
  <keyword>Folfox</keyword>
  <keyword>Response rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

